Related Experiment Video
Updated: Mar 15, 2026

RhoC GTPase Activation Assay
Published on: August 22, 2010
Rho GTPases: Regulation and roles in cancer cell biology
Raquel B Haga1, Anne J Ridley1
1a Randall Division of Cell and Molecular Biophysics, King's College London , London , UK.
Abstract:
Rho GTPases are well known for their roles in regulating cell migration, and also contribute to a variety of other cellular responses. They are subdivided into 2 groups: typical and atypical. The typical Rho family members, including RhoA, Rac1 and Cdc42, cycle between an active GTP-bound and inactive GDP-bound conformation, and are regulated by GEFs, GAPs and GDIs, whereas atypical Rho family members have amino acid substitutions that alter their ability to interact with GTP/GDP and hence are regulated by different mechanisms. Both typical and atypical Rho GTPases contribute to cancer progression. In a few cancers, RhoA or Rac1 are mutated, but in most cancers expression levels and/or activity of Rho GTPases is altered. Rho GTPase signaling could therefore be therapeutically targeted in cancer treatment.
Insights
Rho GTPases regulate cell migration and are implicated in cancer progression. Targeting Rho GTPase signaling pathways offers a potential therapeutic strategy for cancer treatment.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Rho GTPases are key regulators of cell migration and other cellular processes.
- They are classified into typical and atypical groups, with distinct regulatory mechanisms.
- Altered Rho GTPase activity and expression are observed in various cancers.
Purpose of the Study:
- To review the roles of Rho GTPases in cancer progression.
- To highlight the therapeutic potential of targeting Rho GTPase signaling in cancer treatment.
Main Methods:
- Literature review of Rho GTPase function and regulation.
- Analysis of Rho GTPase involvement in different cancer types.
- Exploration of therapeutic targeting strategies.
Main Results:
- Both typical (e.g., RhoA, Rac1, Cdc42) and atypical Rho GTPases contribute to cancer progression.
- Mutations in RhoA or Rac1 occur in some cancers, while altered expression/activity is more common.
- Rho GTPase signaling pathways present viable therapeutic targets.
Conclusions:
- Rho GTPase dysregulation is a significant factor in cancer development and progression.
- Targeting Rho GTPase signaling pathways holds promise for novel cancer therapies.
More Related Videos
13:51Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
11:28Affinity Precipitation of Active Rho-GEFs Using a GST-tagged Mutant Rho Protein GST-RhoAG17A from Epithelial Cell Lysates
Published on: March 31, 2012
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
GTPases and their Regulation
Large G-proteins,...
GTPases and their Regulation
The Ras Gene
Ras is a...
Activation and Inactivation of G Proteins
mTOR Signaling and Cancer Progression
The mTOR pathway or the...